AbbVie reported Q3 adjusted EPS of $3.82 on revenue of $17.404 billion, up 10.3%. Immunology sales rose 16.3% on Skyrizi and Rinvoq strength. The company raised full-year adjusted EPS guidance to $13.95-$13.99 and announced a 5.2% dividend increase. It also completed the Apogee Therapeutics acquisition and reported positive Phase 3 data for lutikizumab in hidradenitis suppurativa.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
